SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor.
SoRelle
R
R
D000284:Administration, Oral; D001569:Benzodiazepines; D017326:Clinical Trials, Phase III as Topic; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D020521:Stroke / Q000517:prevention & control; D016896:Treatment Outcome
D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D001569:Benzodiazepines; C412702:lotrafiban